Reviewing ChromaDex Corporation (CDXC)’s and resTORbio Inc. (NASDAQ:TORC)’s results

This is therefore a contrasting of the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation in ChromaDex Corporation (NASDAQ:CDXC) and resTORbio Inc. (NASDAQ:TORC). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChromaDex Corporation 31.56M 6.55 33.32M -0.63 0.00
resTORbio Inc. N/A 0.00 54.91M -2.06 0.00

In table 1 we can see ChromaDex Corporation and resTORbio Inc.’s gross revenue, earnings per share and valuation.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
ChromaDex Corporation -105.58% -77.8% -61.9%
resTORbio Inc. 0.00% -67.6% -50.1%


ChromaDex Corporation’s Current Ratio is 3.2 while its Quick Ratio is 2.7. On the competitive side is, resTORbio Inc. which has a 14.5 Current Ratio and a 14.5 Quick Ratio. resTORbio Inc. is better positioned to pay off short and long-term obligations compared to ChromaDex Corporation.

Insider and Institutional Ownership

Roughly 17.7% of ChromaDex Corporation shares are owned by institutional investors while 43.7% of resTORbio Inc. are owned by institutional investors. 2.3% are ChromaDex Corporation’s share owned by insiders. Comparatively, 5.7% are resTORbio Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ChromaDex Corporation -6.93% 4.8% -2.24% -22.96% -33.4% 1.75%
resTORbio Inc. 9.49% -1.24% -34.65% -19.47% -52.26% 1.74%

For the past year ChromaDex Corporation was more bullish than resTORbio Inc.


ChromaDex Corporation beats on 5 of the 9 factors resTORbio Inc.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.